View More Recent Stories

Nov 4, 2024 07:51AM Disc Medicine (IRON) Announces Successful End of Phase 2 Meeting with FDA for Bitopertin in Erythropoietic Protoporphyria (EPP), Including Potential for Accelerated Approval
Oct 28, 2024 07:28AM H.C. Wainwright Reiterates Buy Rating on Disc Medicine (iRON)
Oct 25, 2024 01:00PM Disc Medicine (IRON) Presents Positive Data from SAD Cohorts of a Phase 1b Trial in Patients with Chronic Kidney Disease and Anemia
Oct 23, 2024 08:03AM Disc Medicine (IRON) Appoints Seasoned Industry Executive Rahul Kaushik, Ph.D. as Chief Technical Officer
Oct 23, 2024 03:34AM Jefferies Starts Disc Medicine (IRON) at Buy
Sep 19, 2024 08:31AM Disc Medicine (IRON) Expands Leadership Team with Appointment of Industry Veteran Steve Caffé, MD as Chief Regulatory Officer
Sep 16, 2024 07:07AM H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)
Aug 22, 2024 05:30AM Wells Fargo Starts Disc Medicine (IRON) at Overweight
Aug 9, 2024 08:34AM Disc Medicine (IRON) Misses Q2 EPS by 103c
Aug 8, 2024 04:16PM Disc Medicine (IRON) PT Raised to $50 at Raymond James
Jul 10, 2024 08:28AM H.C. Wainwright Reiterates Buy Rating on Disc Medicine (IRON)
Jun 17, 2024 08:21AM Disc Medicine (IRON) PT Raised to $70 at BMO Capital
Jun 14, 2024 08:04AM Disc Medicine (IRON) Announces 4.94M Share Offering at $36/sh
Jun 13, 2024 09:41AM BMO Capital Reiterates Outperform Rating on Disc Medicine (IRON)
View More Recent Stories